Avantor, Rubicon Research collaborate pharma excipients

Avantor, Rubicon Research to collaborate for pharma excipients

4:50 AM, 17th October 2012
Avantor, Rubicon Research to collaborate for pharma excipients
Paul Smaltz, Executive Vice President, Pharmaceuticals and the Americas, Avantor.

CENTER VALLEY, US: Avantor Performance Materials has signed a collaboration agreement with Mumbai-India based, Rubicon Research Pvt Ltd, aimed at combining the company’s proprietary product technology with Avantor’s expertise in manufacturing and marketing to develop next-generation products for the functional excipient market.

The immediate goal of the partnership is to develop and market a novel gastro-retentive excipient which can enable the delivery of molecules having a window of absorption. Introduction of this novel excipient will enable the industry to develop more options in a niche segment where the benefit of targeted delivery will result in significant therapeutic advantage.

“The combination of Rubicon’s groundbreaking technology and our strong position in the global marketplace for functional excipients will result in outstanding products to help our pharmaceutical customers in their pursuit of patient dosage compliance and safety,” said Paul Smaltz, Executive Vice President, Pharmaceuticals and the Americas, Avantor. The company will continue to seek innovative approaches to opportunities in the pharmaceutical area, he added.

The agreement calls for the companies to collaborate on key elements of the process of bringing new products to the pharmaceutical excipient market, including optimized commercial manufacturing and production, regulatory registrations and approvals for full commercialization and potential licensing of the excipient materials.

The two companies said they would work to launch initial products resulting from the partnership in 2013.

“The Rubicon team is excited to work with Avantor in introducing this novel polymeric material as a functional excipient. This material will provide solutions to the global pharmaceutical industry for molecules with challenging therapeutic requirements, either from the pipelines of innovator companies or for life cycle management opportunities for already marketed products,” said Pratibha Pilgaonkar, CEO, Rubicon Research.

© WOC News

 

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


EU ban natural gas import from Iran

TEHRAN, IRAN: The European Union has put a ban on imports of natural gas from Iran to address lingering concerns about the Iranian nuclear programme. ...

Read more
CB&I bags Huating’s polypropylene plant contract in China

THE WOODLANDS, US: CB&I has been awarded a contract by Huating Coal Group Co Ltd for the license, basic engineering and related services for a pol ...

Read more
Showa Denko develops titanium oxide fine particles for photocatalysis

TOKYO, JAPAN: Showa Titanium Co Ltd, a consolidated subsidiary of Showa Denko KK (SDK), has developed titanium oxide fine particles for use in UV-ligh ...

Read more
China extends anti-dumping duties on spandex imports

BEIJING, CHINA: The Ministry of Commerce, China, informed that it will extend its anti-dumping duties on spandex yarn imported from Japan, Singapore, ...

Read more
Water particles found on the moon, say scientists

TENNESSEE, US: The moon’s surface is covered with glassy grains of soil containing significant amounts of water that could sustain human life, a ...

Read more
Styron opens new SSBR production line in Germany

BERWYN, US: Styron opened its new solution styrene butadiene rubber (SSBR) production line, which introduces an additional capacity of 50,000 metric t ...

Read more